2022 Liryc Percutaneous Heart Valve Therapies: From Human Experience to Veterinary Application Thomas Modine See session
2022 Part #2 Panel Discussion ADRIAN BOSWOOD, BERTRAM PITT, FAIEZ ZANNAD, FRÉDÉRIC JAISSER, Jan Danser, Jessica Ward, JONATHAN ELLIOTT, JONATHAN MOCHEL, Luca Ferasin, Mark Oyama, MICHELE BORGARELLI See session
2022 Part #1 MRAs in Heart Failure: a Veterinary and Human Medicine Primary Investigators Cross-talk BERTRAM PITT, FAIEZ ZANNAD See session
2022 Part #1 Breakthrough: When Quantitative Sciences Meet Clinical Practice. Dose Optimization of ACE Inhibitors Through A Systems Pharmacology Approach JONATHAN MOCHEL See session
2022 Part #1 Thoughts and Opinions regarding MRA use in Dogs with Heart Failure Mark Oyama See session
2019 PART #2 Panel discussion BERTRAM PITT, FRÉDÉRIC JAISSER, JONATHAN MOCHEL, LUDOVIC PELLIGAND, MARISA AMES, Mark Oyama, MATHIEU PEYROU, PATRICK ROSSIGNOL See session
2019 PART #2 Overcoming cardiorenal challenges to optimise heart failure management PATRICK ROSSIGNOL See session
2019 PART #1 Efficacy and safety of ISEMID® in dogs with first onset of congestive heart failure: the CARPODIEM and SAFEDIEM studies Mark Oyama See session
2019 PART #1 Harnessing the power of preclinical studies with torasemide to inform a clinical dose LUDOVIC PELLIGAND, MATHIEU PEYROU See session
2016 SESSION 5. DIAGNOSTIC TESTS Questions and answers on diagnostic tests ADRIAN BOSWOOD See session
2016 SESSION 4. MANAGEMENT OF THE HYPERTENSIVE CAT Questions and answers on the Hypertensive cat JONATHAN ELLIOTT See session
2016 SESSION 4. MANAGEMENT OF THE HYPERTENSIVE CAT New Findings influencing management in Feline Hypertension JONATHAN ELLIOTT See session
2016 SESSION 3. MR ANTAGONISTS: CURRENT LIMITS AND NEW CONCEPTS Questions and answers on MR antagonists FRÉDÉRIC JAISSER, MARISA AMES See session
2016 SESSION 3. MR ANTAGONISTS: CURRENT LIMITS AND NEW CONCEPTS Repositioning Mineralocorticoid receptor antagonists in Renal Diseases FRÉDÉRIC JAISSER See session
2016 SESSION 3. MR ANTAGONISTS: CURRENT LIMITS AND NEW CONCEPTS Mineralocorticoid receptor antagonists in canine patients on ACE-I: Where? When? At all? MARISA AMES See session
2016 SESSION 2. RATIONALE USE OF DIURETICS Questions and answers on rationale use of diuretics Mark Oyama, NUALA SUMMERFIELD See session
2016 SESSION 2. RATIONALE USE OF DIURETICS Diminishing returns: Loop Diuretic Resistance in Chronic Heart Failure Mark Oyama See session
2016 SESSION 1. PRE-CLINICAL STAGE OF MITRAL VALVE DISEASE Questions and answers on pre-clinical stage MICHELE BORGARELLI See session
2016 SESSION 1. PRE-CLINICAL STAGE OF MITRAL VALVE DISEASE Is a dog with ACVIM stage B2 chronic degenerative mitral valve disease always pre-clinical? MICHELE BORGARELLI See session
2016 SYMPOSIUM 2016 INTRODUCTION ADRIAN BOSWOOD, CLARKE ATKINS, FAIEZ ZANNAD, FRÉDÉRIC JAISSER, JONATHAN ELLIOTT, MARISA AMES, Mark Oyama, MICHELE BORGARELLI, NUALA SUMMERFIELD See session
2011 SESSION 4. Questions and Answers IV CLARKE ATKINS, Claudio RONCO, FRÉDÉRIC JAISSER, Rebecca STEPIEN See session
2011 SESSION 4. Mineralocorticoid receptor antogonists: New therapeutic opportunities in chronic kidney diseases FRÉDÉRIC JAISSER See session
2011 SESSION 4. A rock and a hard place: cardiorenal syndrome in clinical canine veterinary patients Rebecca STEPIEN See session
2011 SESSION 3. Biomarkers: what are the practical uses and what canbe expected in the coming years? Jens HÄGGSTRÖM See session
2011 SESSION 2. Questions and Answers II BERTRAM PITT, FAIEZ ZANNAD, Jens HÄGGSTRÖM, MICHELE BORGARELLI See session
2011 SESSION 2. The DELAY STUDY (DElay of Appearance of sYmptoms of canine degenerative mitral valve disease treated with Spironolactone and Benazepril) MICHELE BORGARELLI See session
2011 SESSION 2. Treatment of preserved cardiac function heart failure with an Aldosterone antagonist: the NHLBI TOPCAT Trial BERTRAM PITT See session
2011 SESSION 1. Questions and Answers I ADRIAN BOSWOOD, Allan STRUTHERS, CLARKE ATKINS, JONATHAN ELLIOTT See session
2011 SESSION 1. Where are we with aldosterone escape (Break-through) in 2011? CLARKE ATKINS See session
2011 SESSION 1. Aldosterone Receptor antagonists clinical interest: Beyond the “Aldosterone escape” concept Allan STRUTHERS See session
2009 Current clinical status and future directions for biomarkers in heart failure FAIEZ ZANNAD See session
2009 Principles of survival analysis illustrated by CEVA’s spironolactone trials Martin Bland See session
2009 Efficacy of spironolactone in dogs with naturally occurring Myxomatous Mitral Valve Disease. (part II) Claudio Bussadori See session
2009 Efficacy of spironolactone in dogs with naturally occurring Myxomatous Mitral Valve Disease. (part I) Claudio Bussadori See session
2009 The proximate cause of heart failure: models, remodeling, and re-remodeling Robert Hamlin See session
2009 Mineralocorticoid receptor blockade: how experimental evidence supports the clinical benefit Johann Bauersachs See session
2009 Overexpression of the mineralocorticoid receptors: pathophysiological consequences FRÉDÉRIC JAISSER See session
2009 Aldosterone and mineralocortoid receptors: expanding views from the kidney to the cardiovascular system. Nicolette Farman See session
